Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma
AR normally develops within 2 years after the beginning of treatment. Patients with AR have better characteristics in general, less invasive pattens of progression, and better prognosis compared to those with PR. Subsequent local therapy and changes in ICI treatment showed potential to overcome primary resistance.
Authors
- Zixiang Zhou (ORCID: https://orcid.org/0009-0008-5290-9263)
- Chengpei Zhu (ORCID: https://orcid.org/0000-0002-0291-782X)
- Shuofeng Li (ORCID: https://orcid.org/0000-0003-2747-9501)
- Xiangqi Chen (ORCID: https://orcid.org/0000-0003-3367-6261)
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-3444-8044)
- Boyu Sun
- Nan Zhang (ORCID: https://orcid.org/0000-0002-8309-4262)
- Kai Liu (ORCID: https://orcid.org/0000-0001-6039-2681)
- Shanshan Wang (ORCID: https://orcid.org/0000-0002-0575-6523)
- Xu Yang (ORCID: https://orcid.org/0000-0002-5752-7255)
- Xiaohua Shi (ORCID: https://orcid.org/0000-0003-4511-0513)
- Mingjian Piao (ORCID: https://orcid.org/0009-0005-4981-5942)
- Xiaobo Yang (ORCID: https://orcid.org/0000-0001-6164-4131)
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Beijing YouAn Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1007/s00262-025-04184-z
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09